The Boston-based hospital collaborated with XenoTherapeutics to create the tissue graft, known as xenoskin. The graft was genetically modified to remove a gene specific to pigs.
Massachusetts General surgeons transplanted the experimental skin graft and a cadaveric skin graft to a patient’s wound in a recent clinical trial. They removed the grafts five days later.
“Both skin grafts were adherent to the underlying wound bed and appeared indistinguishable from each other,” Massachusetts General said in a news release. “No adverse events were further observed or reported.”
Human skin grafts are costly and often in short supply. The xenografts could offer a cheaper, more widely available option for treating second- and third-degree burns.
More articles on clinical leadership and infection control:
NICU interventions boost infant vaccination rate to 93%
End may be in sight for Congo’s Ebola outbreak
Unattended ER patient dies at Pennsylvania hospital
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.